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Preliminary and Short Report
COMPARISON OF THIABENDAZOLE AND 5-HYDROXY-
THIABENDAZOLE (FOR ANTHELMINTIC EFFECT) *
ORVILLE J. STONE, M.D., J. FEED MULLINS, M.D. AND
CAROLYN J. WILLIS, M.A.
The effectiveness of thiabendazolet in "creeping
eruption" has been reported (1—5). Two studies(6, 7) have shown that the drug has no effect
against the third stage of Ancylostomo coninum,
and one (8) has shown that thiabendazole is capa-
ble of inhibiting the development of this nematode
somewhere between the egg and the infective
stage.Most reported work with thiahendazole has
been performed in vivo. However, in the original
report (9) on this drug, it was stated that it
represented a new class of compounds and that
some of the compounds are among the most potent
chemotherapeutic agents known, with completelarvacidal activity being manifest in vitro at 10"
mcg/ml. The test system was not defined.
A preliminary report (8) showed that thia-
bendazole in a concentration of 125 meg/mi com-
pletely prevented the development of the third
stage larvae from A. contnunt eggs. Further stud-
ies (10) suggested that thiabendazole was being
adsorbed by charcoal used in the culturing proce-
dure, and, therefore, coarse sand was used. The
results of experiments using coarse sand showed
that the minimum effective concentration of thia-
bendazole against A. coninum larvae is 0.1 meg/mi
during the first 48 hours of development and 1.0
mcg/ml at 72 hours. The drug is also effective on
larvae that have undergone 72 hours of develop-
ment in the intestines of the specific host (dog)(10). Concentrations of the drug that kill the or-
ganism before it enters the third stage (infective
form) are exceeded in the blood and skin of sheep
by a single 50 mgm/kgm oral dose (11).
There are several possible explanations for the
effectiveness of thiabendazole in "creeping erup-
tion", in spite of its lack of in vitro effect on the
third stage larvae. Stone et el. (10) have ex-
pressed the opinion that thiabendazole is the
active agent and that it becomes effective after
the larvae progress in development to a stage
where they ingest or become permeable to the
drug. Another possibility is that the drug concen-
trates in the skin; this has not been substantiated
by data supplied from the manufacturer. A third
possibility is that the drug is metabolized in the
patient to a more active substance.
Tocco and Bowers (12) studied the metabolism
of the orally administered drug in eight lambs
using C-14 and S-35 labeled material. Studies em-
ploying countercurrent analysis, paper chroma-
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tography, spectrophotofluorometric analysis and
enzymatic procedures showed that thiabendazole
is almost, completely metabolized to its 5-by-
droxyl derivative and excreted as such and as the
glucuronide and sulfate ester of this metabolite.
The purpose of this paper is to evaluate ,the
anthelmintic properties of the 5-hydroxyl deriva-
tive of thiabendazole.
METIIOO5
The feces of five dogs with known Ancylostome
coninuin infection were gathered and pooled.
Coarse sand was washed and sterilized before use.
In the first study one milliliter of feces was
mixed with 9 ml of water or a solution containing
either thiabendazole or the 5-hydroxy metabohte.
The final concentrations of the thiabendazole and
its 5-hydroxy metabolite were 2.0, 1.0, 0.1, 0.01
and 0.001 mcg/ml. Forty cubic centimeters of
sand were added, mixed, and the material was
stored in a petri dish. The plates were examined at
7 and 10 days for the presence of third stage lar-
vae. All results were clear-cut with either abundant
larvae or no larvae. Thiabendazole in concentra-
tions of 0.1 meg or greater completely inhibited all
development. The metabolite had no effect on
larval development.
In the second study material that was to have
thiabendazole added after 48 to 72 hours of de-
velopment was prepared by mixing 1.0 ml of feces
in 4.0 ml of water and then adding 20 cubic
centimeters of sand. At 48 and 72 hours, 5 ml of a
thiabendazole or a metabolite solution double the
desired final concentrations was added to the
plate. Water controls were used, and an additional
20 cubic centimeters of sand were added. The
concentrations of thiabendazole and 5-hydroxy
thiabendazole were the same as in the first study.
The plates were read in the same manner as in
Study I. Larvae that had reached the normal 48
hour development were completely killed by the
addition of 0.1 mcg/ml or more of thiabendazole,
but the metabohte had no effect on development.
Larvae that had reached the normal 72 hour
development were completely killed by the addi-
tion of 1.0 mg/ml or more of thiabendazole, but
the metabohte had no effect.
RE5ULT5
Thiabendazole was effective in inhibiting de-
velopment of the early stages of A. ceninum in
the same concentrations as previously reported.
However, the maj or metabolite, 5-hydroxythia-
bendazole, had no effect on the system as defined.
The 5-hydroxythiabendazole had no effect even
when used in twenty times the minimum inhibi-
tory concentration of thiabendazole.
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CONCLUSIONS
Thiabendazole is probably the active agent
and in in vitro testing with A. caninum is effective
enough to explain clinical results in "creeping
eruption." The metabolite does not appear to be
active in the test system defined. Thiabendazole
is most likely effective in "creeping eruption" by
its direct effect on the larvae which must progress
in development in the skin to a stage where they
become permeable to the drug.
SUMMARY
The major metabolite of thiabcndazolc, 5-
hydroxythiabendazole, is not effective in inhibit-
ing the early stages of development of A. coninurn
larvae. It did not possess anthelmintic activity in
the test system as defined in this paper.
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